JP Morgan Chase’s Co-Diagnostics CODX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$85 Buy
50
+28
+127% +$96 ﹤0.01% 7322
2025
Q4
$112 Sell
22
-10
-31% -$109 ﹤0.01% 7202
2025
Q3
$332 Sell
32
-443
-93% -$4.12K ﹤0.01% 7079
2025
Q2
$3.99K Buy
475
+472
+15,733% +$4.42K ﹤0.01% 6443
2025
Q1
$24 Hold
3
﹤0.01% 7093
2024
Q4
$57 Hold
3
﹤0.01% 7103
2024
Q3
$95 Hold
3
﹤0.01% 7009
2024
Q2
$95 Hold
3
﹤0.01% 6899
2024
Q1
$85 Hold
3
﹤0.01% 6934
2023
Q4
$101 Hold
3
﹤0.01% 7123
2023
Q3
$81 Hold
3
﹤0.01% 6936
2023
Q2
$84 Hold
3
﹤0.01% 6709
2023
Q1
$0 Hold
3
﹤0.01% 6756
2022
Q4
$0 Hold
3
﹤0.01% 6599
2022
Q3
$0 Hold
3
﹤0.01% 6497
2022
Q2
$0 Hold
3
﹤0.01% 6513
2022
Q1
$0 Hold
3
﹤0.01% 6642
2021
Q4
$1K Hold
3
﹤0.01% 6548
2021
Q3
$1K Sell
3
-1
-25% -$292 ﹤0.01% 6378
2021
Q2
$1K Sell
4
-2,498
-100% -$642K ﹤0.01% 6237
2021
Q1
$715K Buy
2,502
+2,107
+533% +$841K ﹤0.01% 4454
2020
Q4
$109K Sell
395
-2,448
-86% -$907K ﹤0.01% 4982
2020
Q3
$1.19M Buy
2,843
+2,122
+294% +$1.09M ﹤0.01% 3554
2020
Q2
$419K Buy
+721
New +$329K ﹤0.01% 3925

Other funds holding CODX

JP Morgan Chase's CODX Position: Q1 2026 in Review

JP Morgan Chase increased its Co-Diagnostics (CODX) stake by 127% in Q1 2026, buying an estimated $96 and bringing the position to 50 shares worth $85. The position accounts for ﹤0.01% of the portfolio, ranked #7322.

JP Morgan Chase first reported a position in CODX in Q2 2020 and has held it in 24 quarters since. The position peaked at $1.19M in Q3 2020. 14 funds tracked by Wall St. Rank hold CODX as of Q1 2026.

  • JP Morgan Chase held 50 shares of Co-Diagnostics worth $85 as of Q1 2026.
  • JP Morgan Chase bought 28 Co-Diagnostics shares in Q1 2026, an estimated $96.
  • Co-Diagnostics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #7322 holding.
  • JP Morgan Chase first reported a position in Co-Diagnostics in Q2 2020 and has held it in 24 quarters since.
  • JP Morgan Chase's Co-Diagnostics position peaked at $1.19M in Q3 2020.
  • 14 funds tracked by Wall St. Rank held Co-Diagnostics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.